Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46155 | 0.86 | TSHR (0.72) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL867412 | 0.78 | TSHR (0.62) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL9772982 | 0.75 | KCNH2 (0.44) | TSHRDRD1 | |
| SCHEMBL9772734 | 0.75 | KCNH2 (0.44) | TSHRDRD1 | |
| SCHEMBL9772728 | 0.75 | KCNH2 (0.44) | TSHRDRD1 | |
| SCHEMBL1120426 | 0.74 | TSHR (0.56) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL531416 | 0.74 | TSHR (0.56) | TSHRGSTO1 | |
| SCHEMBL13472299 | 0.74 | TSHR (0.56) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL13450817 | 0.74 | TSHR (0.56) | TSHRCHRM2CHRM3CHRM4CHRM1 | |
| SCHEMBL1583198 | 0.74 | TSHR (0.56) | TSHRGSTO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2019-01-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-9328198-B2 | Composition for forming resist underlayer | AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (LU) | 2016-05-03 | — | — | US | disclosed |
| US-9328198-B2 | Composition for forming resist underlayer | AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (LU) | 2016-05-03 | — | — | US | disclosed |
| US-9328198-B2 | Composition for forming resist underlayer | AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (LU) | 2016-05-03 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150118624-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER | AZ ELECTRONIC MATERIALS S.À R.L. (LU) | 2015-04-30 | — | — | US | disclosed |
| US-20150118624-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER | AZ ELECTRONIC MATERIALS S.À R.L. (LU) | 2015-04-30 | — | — | US | disclosed |
| US-20150118624-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER | AZ ELECTRONIC MATERIALS S.À R.L. (LU) | 2015-04-30 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| CN-1369565-A | Process for preparing chiral substituted arylepoxyethane compounds and its biol by selective splitting of Aspergillus niger | SHANGHAI INST ORGANIC CHEM (CN) | 2002-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | TSHR 4633/4885CHRM2 4524/4885CHRM3 4013/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | TSHR 4633/4885CHRM2 4524/4885CHRM3 4013/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | TSHR 4633/4885CHRM2 4524/4885CHRM3 4013/4885 |
| US-20190016732-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | TSHR 4633/4885CHRM2 4524/4885CHRM3 4013/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | TSHR 4633/4885CHRM2 4524/4885CHRM3 4013/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | TSHR 4633/4885CHRM2 4524/4885CHRM3 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.